Linked Life Data

2199618

Source:http://linkedlifedata.com/resource/pubmed/id/2199618

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1990-9-7
pubmed:abstractText
Between November 1, 1983 and June 30, 1987, 510 node-positive, estrogen receptor (ER)-positive breast cancer patients have been randomly allocated to receive either chemotherapy (six intravenous [IV] cyclophosphamide, methotrexate, and fluorouracil [CMF] courses followed by four IV epirubicin courses) or 5 years of tamoxifen treatment or a combination of both therapies. After a median follow-up of 40 months, patients receiving the combined treatment achieved the best results, and those treated with chemotherapy alone achieved the worst, the difference being particularly evident in postmenopausal women. However, while the concurrent use of chemotherapy and tamoxifen did improve the results achieved by chemotherapy alone, particularly in postmenopausal women and in those with four or more involved nodes, it did not significantly improve the results achieved by tamoxifen alone, particularly in patients with higher ER tumor concentrations. Side effects were more numerous and more severe in patients receiving chemotherapy (with or without tamoxifen). Our findings, although still preliminary, confirm that tamoxifen should be the treatment of choice for postmenopausal breast cancer patients with node-positive, ER-positive tumors. In addition, the findings suggest that tamoxifen may represent a safe alternative to chemotherapy (at least to the cytotoxic regimen we used) for younger women, provided they have ER-positive tumors. In patients with ER-positive tumors, the addition of chemotherapy to tamoxifen does not seem to improve significantly the effectiveness of tamoxifen alone.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
1310-20
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:2199618-Adult, pubmed-meshheading:2199618-Aged, pubmed-meshheading:2199618-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:2199618-Breast Neoplasms, pubmed-meshheading:2199618-Combined Modality Therapy, pubmed-meshheading:2199618-Cyclophosphamide, pubmed-meshheading:2199618-Epirubicin, pubmed-meshheading:2199618-Female, pubmed-meshheading:2199618-Fluorouracil, pubmed-meshheading:2199618-Follow-Up Studies, pubmed-meshheading:2199618-Humans, pubmed-meshheading:2199618-Italy, pubmed-meshheading:2199618-Lymph Nodes, pubmed-meshheading:2199618-Lymphatic Metastasis, pubmed-meshheading:2199618-Menopause, pubmed-meshheading:2199618-Methotrexate, pubmed-meshheading:2199618-Middle Aged, pubmed-meshheading:2199618-Multicenter Studies as Topic, pubmed-meshheading:2199618-Multivariate Analysis, pubmed-meshheading:2199618-Prospective Studies, pubmed-meshheading:2199618-Random Allocation, pubmed-meshheading:2199618-Receptors, Estrogen, pubmed-meshheading:2199618-Tamoxifen
pubmed:year
1990
pubmed:articleTitle
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
pubmed:affiliation
Istituto Nazionale per la Ricerca sul Cancro, Istituto di Oncologia dell Universita, Genova, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study